University of Colorado Denver, Anschutz Medical Campus, Aurora, CO, USA.
Urology. 2012 Oct;80(4):754-62. doi: 10.1016/j.urology.2012.05.006. Epub 2012 Jul 13.
Androgen deprivation therapy is frequently used to treat patients with advanced prostate cancer. New therapies for metastatic castration-resistant prostate cancer have drawn increased attention to serum and intratumoral testosterone levels. The present review examines the role of testosterone in prostate cancer progression, discusses the nuances and potential pitfalls in measuring serum testosterone using available assays, and summarizes current data relevant to the arguments for and against achieving and maintaining the lowest possible testosterone levels during androgen deprivation therapy, including the adverse effects of such treatment. Incorporating this information, we have made recommendations incorporating testosterone evaluation and its effect on the clinical decision-making process.
雄激素剥夺疗法常用于治疗晚期前列腺癌患者。转移性去势抵抗性前列腺癌的新疗法引起了人们对血清和肿瘤内睾酮水平的更多关注。本综述探讨了睾酮在前列腺癌进展中的作用，讨论了使用现有检测方法测量血清睾酮的细微差别和潜在陷阱，并总结了与雄激素剥夺治疗期间达到并维持尽可能低的睾酮水平的论据相关的当前数据，包括这种治疗的不良反应。结合这些信息，我们提出了建议，包括睾酮评估及其对临床决策过程的影响。
